肌肉松弛剂治疗成人非特异性腰背痛:系统综述与Meta分析
该系统综述与Meta分析纳入49项随机对照试验(其中31项、6505名受试者进入定量分析),评估肌肉松弛剂对成人非特异性腰背痛的疗效、可接受性与安全性。急性腰背痛中,非苯二氮䓬类解痉药在≤2周时疼痛强度降幅很小且不具临床重要性,不良反应风险可能增加,可接受性无显著差异;证据确定性极低至低,亟需高质量安慰剂对照试验。
要点
- 非苯二氮䓬类解痉药在急性腰背痛≤2周时疼痛降幅很小,不具临床重要性。
- 该类药物可能增加不良反应风险,可接受性(因任何原因停药)与对照无显著差异。
- 整体证据确定性极低至低,多数试验高偏倚风险,临床决策需谨慎。
核心结论
- 肌肉松弛剂治疗非特异性腰背痛的临床疗效与安全性存在很大不确定性。
- 极低至低确定性证据显示非苯二氮䓬类解痉药在急性腰背痛≤2周时仅小幅降低疼痛强度且不具临床重要性,并可能增加不良反应风险。
- 亟需大型、高质量、安慰剂对照试验以解决不确定性。
研究设计与样本
- 系统综述与随机对照试验的Meta分析,检索Medline、Embase、CINAHL、CENTRAL、ClinicalTrials.gov、clinicaltrialsregister.eu和WHO ICTRP自建库至2021年2月23日。
- 纳入成人(≥18岁)非特异性腰背痛、比较肌肉松弛剂与安慰剂、常规照护、等待名单或无治疗的随机对照试验。
- 共纳入49项试验,其中31项(6505名受试者)进行定量分析。
- 采用Cochrane偏倚风险工具和GRADE评估偏倚风险与证据确定性,使用限制最大似然估计的随机效应Meta分析模型估计合并效应及95%CI。
主要发现
- 急性腰背痛≤2周时,非苯二氮䓬类解痉药与对照相比疼痛强度降低(均差-7.7,95%CI -12.1至-3.3),但残疾无改善(-3.3,-7.3至0.7),证据确定性极低。
- 急性腰背痛中,非苯二氮䓬类解痉药可能增加不良事件风险(相对风险1.6,95%CI 1.2至2.0),证据确定性低。
- 急性腰背痛中,非苯二氮䓬类解痉药对可接受性(因任何原因停药)可能几乎无影响(相对风险0.8,95%CI 0.6至1.1),证据确定性极低。
- 研究其他肌肉松弛剂及不同腰背痛持续时间的试验数量少,且多数试验高偏倚风险导致证据确定性降低。
关键数值与推荐
- 急性腰背痛≤2周:非苯二氮䓬类解痉药 vs 对照,疼痛强度均差-7.7(95%CI -12.1至-3.3),残疾均差-3.3(95%CI -7.3至0.7)。
- 急性腰背痛:非苯二氮䓬类解痉药 vs 对照,不良事件相对风险1.6(95%CI 1.2至2.0),可接受性相对风险0.8(95%CI 0.6至1.1)。
临床怎么用
- 对急性非特异性腰背痛患者,不应高估非苯二氮䓬类解痉药的获益,其疼痛降幅很小且不具临床重要性。
- 处方非苯二氮䓬类解痉药时需权衡可能增加的不良事件风险。
- 临床决策应结合证据确定性极低至低的现状,并与患者充分沟通不确定性。
局限性
- 多数试验高偏倚风险,降低了证据确定性。
- 研究其他肌肉松弛剂及不同腰背痛持续时间的试验数量少。
- 证据确定性极低至低,结论存在很大不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy, acceptability, and safety of muscle relaxants for low back pain. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, CINAHL, CENTRAL, ClinicalTrials.gov, clinicialtrialsregister.eu, and WHO ICTRP from inception to 23 February 2021. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised controlled trials of muscle relaxants compared with placebo, usual care, waiting list, or no treatment in adults (≥18 years) reporting non-specific low back pain. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently identified studies, extracted data, and assessed the risk of bias and certainty of the evidence using the Cochrane risk-of-bias tool and Grading of Recommendations, Assessment, Development and Evaluations, respectively. Random effects meta-analytical models through restricted maximum likelihood estimation were used to estimate pooled effects and corresponding 95% confidence intervals. Outcomes included pain intensity (measured on a 0-100 point scale), disability (0-100 point scale), acceptability (discontinuation of the drug for any reason during treatment), and safety (adverse events, serious adverse events, and number of participants who withdrew from the trial because of an adverse event). RESULTS: 49 trials were included in the review, of which 31, sampling 6505 participants, were quantitatively analysed. For acute low back pain, very low certainty evidence showed that at two weeks or less non-benzodiazepine antispasmodics were associated with a reduction in pain intensity compared with control (mean difference -7.7, 95% confidence interval-12.1 to-3.3) but not a reduction in disability (-3.3, -7.3 to 0.7). Low and very low certainty evidence showed that non-benzodiazepine antispasmodics might increase the risk of an adverse event (relative risk 1.6, 1.2 to 2.0) and might have little to no effect on acceptability (0.8, 0.6 to 1.1) compared with control for acute low back pain, respectively. The number of trials investigating other muscle relaxants and different durations of low back pain were small and the certainty of evidence was reduced because most trials were at high risk of bias. CONCLUSIONS: Considerable uncertainty exists about the clinical efficacy and safety of muscle relaxants. Very low and low certainty evidence shows that non-benzodiazepine antispasmodics might provide small but not clinically important reductions in pain intensity at or before two weeks and might increase the risk of an adverse event in acute low back pain, respectively. Large, high quality, placebo controlled trials are urgently needed to resolve uncertainty. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019126820 and Open Science Framework https://osf.io/mu2f5/.
引用
- Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ. 2021. PMID: 34233900. doi:10.1136/bmj.n1446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。